T 2347/19 (Blinatumomab neurological adverse events/AMGEN) of 04.07.2023
- European Case Law Identifier
- ECLI:EP:BA:2023:T234719.20230704
- Date of decision
- 4 July 2023
- Case number
- T 2347/19
- Petition for review of
- -
- Application number
- 11788077.3
- IPC class
- A61K 31/573A61K 39/395
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- PREVENTION OF ADVERSE EFFECTS CAUSED BY CD3 SPECIFIC BINDING DOMAINS
- Applicant name
- Amgen Research (Munich) GmbH
- Opponent name
- F.Hoffmann-La Roche AG
Lindis Biotech GmbH - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 56European Patent Convention Art 83Rules of procedure of the Boards of Appeal Art 12(4)
- Keywords
- Sufficiency of disclosure - after amendment
Inventive step - after amendment - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeals are dismissed.